- Home
- PAYS vs LRMR Comparison
PAYS vs LRMR Comparison
Compare PAYS & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | LRMR |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 455.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PAYS | LRMR |
|---|---|---|
| Price | $8.68 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $9.42 | ★ $16.50 |
| AVG Volume (30 Days) | 577.2K | ★ 2.6M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $24,120,434.00 | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | $1,816.14 |
| P/E Ratio | $93.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $2.72 |
| 52 Week High | $9.30 | $6.42 |
Technical Indicators
Market Signals| Indicator | PAYS | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 60.14 |
| Support Level | $4.94 | $3.87 |
| Resistance Level | $9.30 | $4.32 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 50.91 | 78.83 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.